Analysts forecast that Integra Lifesciences Holdings Corp (NASDAQ:IART) will report earnings of $0.59 per share for the current quarter, according to Zacks. Six analysts have issued estimates for Integra Lifesciences’ earnings, with estimates ranging from $0.58 to $0.60. Integra Lifesciences reported earnings of $0.45 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 31.1%. The company is expected to announce its next earnings results on Thursday, October 25th.

According to Zacks, analysts expect that Integra Lifesciences will report full year earnings of $2.40 per share for the current financial year, with EPS estimates ranging from $2.39 to $2.44. For the next fiscal year, analysts expect that the business will post earnings of $2.73 per share, with EPS estimates ranging from $2.66 to $2.76. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Integra Lifesciences.

Integra Lifesciences (NASDAQ:IART) last released its earnings results on Wednesday, July 25th. The life sciences company reported $0.60 EPS for the quarter, hitting analysts’ consensus estimates of $0.60. Integra Lifesciences had a return on equity of 17.43% and a net margin of 5.10%. The firm had revenue of $366.20 million for the quarter, compared to analysts’ expectations of $368.08 million. During the same period in the prior year, the firm posted $0.45 earnings per share. The company’s quarterly revenue was up 29.8% on a year-over-year basis.

IART has been the topic of several recent analyst reports. Oppenheimer set a $74.00 price objective on Integra Lifesciences and gave the company a “buy” rating in a research report on Friday, June 1st. Zacks Investment Research cut Integra Lifesciences from a “hold” rating to a “sell” rating in a research report on Tuesday, July 10th. Citigroup increased their price objective on Integra Lifesciences from $60.00 to $70.00 and gave the company an “outperform” rating in a research report on Thursday, April 26th. BidaskClub raised Integra Lifesciences from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 8th. Finally, JPMorgan Chase & Co. increased their price objective on Integra Lifesciences from $55.00 to $57.00 and gave the company a “neutral” rating in a research report on Thursday, April 26th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $61.38.

In other Integra Lifesciences news, VP Daniel L. Reuvers sold 1,000 shares of the stock in a transaction dated Friday, June 15th. The stock was sold at an average price of $66.97, for a total value of $66,970.00. Following the transaction, the vice president now owns 25,009 shares of the company’s stock, valued at $1,674,852.73. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Glenn Coleman sold 8,916 shares of the stock in a transaction dated Thursday, August 9th. The shares were sold at an average price of $63.00, for a total value of $561,708.00. Following the completion of the transaction, the vice president now directly owns 16,795 shares in the company, valued at approximately $1,058,085. The disclosure for this sale can be found here. In the last three months, insiders sold 271,892 shares of company stock worth $17,347,342. 5.10% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Zeke Capital Advisors LLC bought a new position in shares of Integra Lifesciences in the second quarter worth about $204,000. We Are One Seven LLC raised its stake in shares of Integra Lifesciences by 4,497.1% in the first quarter. We Are One Seven LLC now owns 3,218 shares of the life sciences company’s stock worth $178,000 after buying an additional 3,148 shares during the period. Eagle Boston Investment Management Inc. bought a new position in shares of Integra Lifesciences in the second quarter worth about $223,000. Coldstream Capital Management Inc. bought a new position in shares of Integra Lifesciences in the first quarter worth about $207,000. Finally, Stanley Laman Group Ltd. bought a new position in shares of Integra Lifesciences in the first quarter worth about $221,000. 81.99% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ IART traded down $0.61 during trading on Tuesday, reaching $58.97. The company had a trading volume of 865,821 shares, compared to its average volume of 751,292. Integra Lifesciences has a 12-month low of $41.51 and a 12-month high of $67.50. The stock has a market cap of $5.35 billion, a P/E ratio of 30.40, a P/E/G ratio of 1.94 and a beta of 0.57. The company has a current ratio of 3.52, a quick ratio of 2.27 and a debt-to-equity ratio of 1.10.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Featured Article: Leveraged Buyout (LBO)

Get a free copy of the Zacks research report on Integra Lifesciences (IART)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.